Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $366
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $357 to $366.
August 02, 2024 | 11:44 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Alnylam Pharmaceuticals and raises the price target from $357 to $366.
The raised price target and maintained Buy rating from a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100